Top 5 High Tech Stocks To Buy For 2019

Executive Summary

Since 2009, Skyworks Solutions (NASDAQ:SWKS) has outperformed major equity-market benchmarks by a wide margin. Over a period of seven years ending in mid-2015, the stock rallied from $3.5 to $113. However, after June 2015, the upward trend reversed and a price drop of approximately 50% followed in a period of a wide stock market correction. Over the same period, (adjusted) revenue rose from $0.860 billion (FY 2008) to $3.289 billion (FY 2016). Adjusted earnings per share increased almost tenfold from $0.57 to $4.93. As of Friday December 23, 2016, the stock price is at $78.03.

Click to enlarge

Top 5 High Tech Stocks To Buy For 2019: Microbot Medical Inc. (MBOT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Microbot Medical Inc (NASDAQ: MBOT) shares dropped 34 percent to $2.50. Microbot Medical reported a $10 million registered direct offering

    Shares of NewLink Genetics Corp (NASDAQ: NLNK) were down 12 percent to $11.13 after the company reported that indoximod + PROVENGE resulted in statistically significant improvement in rPFS for patients with mCRPC in Phase 2 trial.

  • [By Lisa Levin]

    Shares of Microbot Medical Inc (NASDAQ: MBOT) got a boost, shooting up 15 percent to $8.77 after the company reported a 700,000 share direct offering for $3.5 million.

  • [By Lisa Levin]

    Microbot Medical Inc (NASDAQ: MBOT) shares shot up 51 percent to $7.76 after reporting a significant technology patent allowance in the U.S. The patent allowance covers a device for the prevention of shunt stenosis.

Top 5 High Tech Stocks To Buy For 2019: Wins Finance Holdings Inc.(WINS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Friday afternoon, the financial sector proved to be a source of strength for the market. Leading the sector was strength from Wins Finance Holdings Inc (NASDAQ: WINS) and Old Second Bancorp Inc. (NASDAQ: OSBC).

  • [By Lisa Levin]

    On Friday, the financial sector proved to be a source of strength for the market. Leading the sector was strength from Wins Finance Holdings Inc (NASDAQ: WINS) and Navient Corp (NASDAQ: NAVI).

Top 5 High Tech Stocks To Buy For 2019: AmerisourceBergen Corporation (Holding Co)(ABC)

Advisors’ Opinion:

  • [By Logan Wallace]

    AmerisourceBergen (NYSE: ABC) and Trxade Group (OTCMKTS:TRXD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.

  • [By Ethan Ryder]

    Alphabit (CURRENCY:ABC) traded down 14.2% against the US dollar during the 24-hour period ending at 19:00 PM Eastern on April 11th. Alphabit has a market cap of $0.00 and approximately $999.00 worth of Alphabit was traded on exchanges in the last 24 hours. One Alphabit token can now be purchased for about $33.91 or 0.00489408 BTC on cryptocurrency exchanges including C-CEX and Cryptopia. In the last week, Alphabit has traded up 2.4% against the US dollar.

  • [By Ben Levisohn]

    AmerisourceBergen (ABC) sprinted to the top of the S&P 500 after releasing Street-beating earnings this morning.

    Getty Images

    Shares of AmerisourceBergen jumped 8.8% to $$75.96 today, while the S&P 500 dropped fell 0.7% to 2,097.94.

    Leerink’s David Larsen and Matt Dellelo traces today’s big gain to Amerisource’s big drop following McKesson’s (MCK) earnings last week:

    This morningAmerisourceBergen reported adjusted EPS of $1.30, which was well ahead of Leerink/consensus of $1.22/$1.22. The quality of the beat appears decent, with some pressure in gross margin, completely offset by lower SG&A costs. Given the dramatic reduction in guidance provided byMcKesson (MP), investors had been very cautious heading into the quarter. We are pleased to see that F2017 EPS guidance of $5.63-$5.88 brackets Leerink/consensus estimates of $5.85/$5.82. Brand inflation is now expected to be in the +7-9% range from 10% previously, and F2017 is expected to be back-half loaded. Our first impression of the quarter is that the print and guide are good and there will likely be a relief rally in the shares.

    AmerisourceBergen’s market capitalization rose to $18.1 billion from $16.6 billion yesterday.

Top 5 High Tech Stocks To Buy For 2019: Simulations Plus, Inc.(SLP)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, healthcare shares fell by 0.88 percent. Meanwhile, top losers in the sector included Simulations Plus, Inc. (NASDAQ: SLP), down 7 percent, and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), down 7 percent.

  • [By Stephan Byrd]

    Simulations Plus (NASDAQ:SLP) shares hit a new 52-week high and low during mid-day trading on Monday . The company traded as low as $18.55 and last traded at $18.35, with a volume of 49668 shares changing hands. The stock had previously closed at $18.20.

Top 5 High Tech Stocks To Buy For 2019: Shire plc(SHPG)

Advisors’ Opinion:

  • [By Ben Levisohn]

    We highlight the key takeaways below, which have read-throughs for brand drug companies we cover such asAllergan (AGN), Shire (SHPG), Valeant Pharmaceuticals International, Mallinckrodt,Endo International and Jazz Pharmaceuticals (JAZZ), among others.

  • [By Jim Robertson]

    That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:

    From May 2010 to May 2015, she was the VP, Regulatory Affairs at AbbVie Inc (NYSE: ABBV) leading the executive functions related to regulatory policy and intelligence. From August 1993 to January 2005, she held positions of increasing responsibility with Pfizer Inc (NYSE: PFE), formerly Wyeth.  From January 2005 to April 2010, she held positions with Shire PLC (NASDAQ: SHPG), including serving as Senior Director, Regulatory Affairs. This included responsibilities as Therapeutic Area Head for Shire’s Gastrointestinal Business Unit, Regulatory Advertising & Promotion and CMC. Rockney led the regulatory team and negotiations with the FDA for LIALDA which are part of the drug class of aminosalicylates that are now part of the clinical standard-of-care for treating inflammatory bowel disease. LIALDA™ was found to be effective in Phase 3 trials for inducing remission of active mild-to-moderate ulcerative colitis after eight weeks of treatment. LIALDA™ (also now marketed as Mezavant®) had 2016 U.S. sales of $714 million – up 16% relative to 2015 sales.

    Rockney’s work for Shire is of particular interest to Vitality Biopharma which has developed a new class of cannabinoid prodrugs (medications or compounds that, after administration, are converted within the body into a pharmacologically active drug), known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Cannabosides could provide therapeutic benefits for infl

  • [By Todd Campbell]

    Takeda Pharmaceutical Co. (NASDAQOTH:TKPYY) announced late last month its interest in making an offer to acquire Shire (NASDAQ:SHPG), and according to Shire, Takeda has followed through with three separate bids. So far, Shire’s board of directors has rejected the offers as inadequate, but that doesn’t mean another offer won’t convince them otherwise. It’s unclear if Takeda will make yet another bid, or when it might do so. But even if it doesn’t, a deal could still be struck.

  • [By Benzinga News Desk]

    Takeda Pharmaceutical Co. on Tuesday reached an agreement to buy Shire PLC (NASDAQ: SHPG), capping a months long battle for control of the European drugmaker and marking the biggest-ever overseas acquisition by a Japanese company: Link $

  • [By Benzinga News Desk]

    Takeda Pharmaceutical Co. moved closer to securing a $64 billion takeover of Shire PLC (NASDAQ: SHPG) after the target said it was willing to recommend that shareholders accept the Japanese firm’s latest proposal and extended a deadline to reach a definitive agreement: Link $

Leave a Reply

Your email address will not be published. Required fields are marked *